AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T FailureAdvanced small-cell lung cancer, Business, Clinical Trials, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hematology, Job Cuts, Metastatic Melanoma, Oncology, Pancreatic Cancer, Prostate Cancer, R&DAbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco. Read more March 29, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-03-29 12:20:372019-03-29 12:59:44AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure
